ParkinsonCanadaV1, Main, Exploration, bibRecord, 001A53

Effects of Hydrogen Sulfide-releasing l-DOPA Derivatives on Glial Activation

Identifieur interne : 001A53 ( Main/Exploration ); précédent : 001A52; suivant : 001A54

Effects of Hydrogen Sulfide-releasing l-DOPA Derivatives on Glial Activation

Auteurs : Moonhee Lee ; Valerio Tazzari ; Daniela Giustarini ; Ranieri Rossi ; Anna Sparatore ; Piero Del Soldato [Italie] ; Edith Mcgeer ; Patrick L. Mcgeer

Source :

The Journal of Biological Chemistry [ 0021-9258 ] ; 2010.

RBID : PMC:2878495

English descriptors

KwdEn :
- Animals, Cell Line, Cell Line, Tumor, Humans, Hydrogen Sulfide (chemistry), Interleukin-6 (metabolism), Levodopa (metabolism), Mitochondria (metabolism), Models, Biological, Neuroglia (metabolism), Neuroprotective Agents (pharmacology), Nitric Oxide (metabolism), Parkinson Disease (therapy), Rats, Tumor Necrosis Factor-alpha (metabolism).
MESH :
- chemical , chemistry : Hydrogen Sulfide.
- chemical , metabolism : Interleukin-6, Levodopa, Nitric Oxide, Tumor Necrosis Factor-alpha.
- metabolism : Mitochondria, Neuroglia.
- chemical , pharmacology : Neuroprotective Agents.
- therapy : Parkinson Disease.
- Animals, Cell Line, Cell Line, Tumor, Humans, Models, Biological, Rats.

Abstract

The main lesion in Parkinson disease (PD) is loss of substantia nigra dopaminergic neurons. Levodopa (l-DOPA) is the most widely used therapy, but it does not arrest disease progression. Some possible contributing factors to the continuing neuronal loss are oxidative stress, including oxidation of l-DOPA, and neurotoxins generated by locally activated microglia and astrocytes. A possible method of reducing these factors is to produce l-DOPA hybrid compounds that have antioxidant and antiinflammatory properties. Here we demonstrate the properties of four such l-DOPA hybrids based on coupling l-DOPA to four different hydrogen sulfide-donating compounds. The donors themselves were shown to be capable of conversion by isolated mitochondria to H₂S or equivalent SH⁻ ions. This capability was confirmed by in vivo results, showing a large increase in intracerebral dopamine and glutathione after iv administration in rats. When human microglia, astrocytes, and SH-SY5Y neuroblastoma cells were treated with these donating agents, they all accumulated H₂S intracellularly as did their derivatives coupled to l-DOPA. The donating agents and the l-DOPA hybrids reduced the release of tumor necrosis factor-α, interleukin-6, and nitric oxide from stimulated microglia, astrocytes as well as the THP-1 and U373 cell lines. They also demonstrated a neuroprotective effect by reducing the toxicity of supernatants from these stimulated cells to SH-SY5Y cells. l-DOPA itself was without effect in any of these assays. The H₂S-releasing l-DOPA hybrid molecules also inhibited MAO B activity. They may be useful for the treatment of PD because of their significant antiinflammatory, antioxidant, and neuroprotective properties.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878495

DOI: 10.1074/jbc.M110.115261
PubMed: 20368333
PubMed Central: 2878495

Affiliations:

Italie

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of Hydrogen Sulfide-releasing <sc>l</sc>
-DOPA Derivatives on Glial Activation</title>
<author><name sortKey="Lee, Moonhee" sort="Lee, Moonhee" uniqKey="Lee M" first="Moonhee" last="Lee">Moonhee Lee</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Tazzari, Valerio" sort="Tazzari, Valerio" uniqKey="Tazzari V" first="Valerio" last="Tazzari">Valerio Tazzari</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Giustarini, Daniela" sort="Giustarini, Daniela" uniqKey="Giustarini D" first="Daniela" last="Giustarini">Daniela Giustarini</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rossi, Ranieri" sort="Rossi, Ranieri" uniqKey="Rossi R" first="Ranieri" last="Rossi">Ranieri Rossi</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sparatore, Anna" sort="Sparatore, Anna" uniqKey="Sparatore A" first="Anna" last="Sparatore">Anna Sparatore</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Del Soldato, Piero" sort="Del Soldato, Piero" uniqKey="Del Soldato P" first="Piero" last="Del Soldato">Piero Del Soldato</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">CTG Pharma, Viale Gran Sasso 17, 20131 Milano, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>CTG Pharma, Viale Gran Sasso 17, 20131 Milano</wicri:regionArea>
<wicri:noRegion>20131 Milano</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcgeer, Edith" sort="Mcgeer, Edith" uniqKey="Mcgeer E" first="Edith" last="Mcgeer">Edith Mcgeer</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L." last="Mcgeer">Patrick L. Mcgeer</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20368333</idno>
<idno type="pmc">2878495</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878495</idno>
<idno type="RBID">PMC:2878495</idno>
<idno type="doi">10.1074/jbc.M110.115261</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">000550</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000550</idno>
<idno type="wicri:Area/Pmc/Curation">000550</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000550</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000A47</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A47</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000D41</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D41</idno>
<idno type="wicri:Area/PubMed/Curation">000D41</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D41</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D41</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D41</idno>
<idno type="wicri:Area/Ncbi/Merge">000C43</idno>
<idno type="wicri:Area/Ncbi/Curation">000C43</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000C43</idno>
<idno type="wicri:doubleKey">0021-9258:2010:Lee M:effects:of:hydrogen</idno>
<idno type="wicri:Area/Main/Merge">001B61</idno>
<idno type="wicri:Area/Main/Curation">001A53</idno>
<idno type="wicri:Area/Main/Exploration">001A53</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Effects of Hydrogen Sulfide-releasing <sc>l</sc>
-DOPA Derivatives on Glial Activation</title>
<author><name sortKey="Lee, Moonhee" sort="Lee, Moonhee" uniqKey="Lee M" first="Moonhee" last="Lee">Moonhee Lee</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Tazzari, Valerio" sort="Tazzari, Valerio" uniqKey="Tazzari V" first="Valerio" last="Tazzari">Valerio Tazzari</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Giustarini, Daniela" sort="Giustarini, Daniela" uniqKey="Giustarini D" first="Daniela" last="Giustarini">Daniela Giustarini</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rossi, Ranieri" sort="Rossi, Ranieri" uniqKey="Rossi R" first="Ranieri" last="Rossi">Ranieri Rossi</name>
<affiliation><nlm:aff id="aff3"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sparatore, Anna" sort="Sparatore, Anna" uniqKey="Sparatore A" first="Anna" last="Sparatore">Anna Sparatore</name>
<affiliation><nlm:aff id="aff2"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Del Soldato, Piero" sort="Del Soldato, Piero" uniqKey="Del Soldato P" first="Piero" last="Del Soldato">Piero Del Soldato</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">CTG Pharma, Viale Gran Sasso 17, 20131 Milano, Italy</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>CTG Pharma, Viale Gran Sasso 17, 20131 Milano</wicri:regionArea>
<wicri:noRegion>20131 Milano</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcgeer, Edith" sort="Mcgeer, Edith" uniqKey="Mcgeer E" first="Edith" last="Mcgeer">Edith Mcgeer</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L." last="Mcgeer">Patrick L. Mcgeer</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of Biological Chemistry</title>
<idno type="ISSN">0021-9258</idno>
<idno type="eISSN">1083-351X</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Hydrogen Sulfide (chemistry)</term>
<term>Interleukin-6 (metabolism)</term>
<term>Levodopa (metabolism)</term>
<term>Mitochondria (metabolism)</term>
<term>Models, Biological</term>
<term>Neuroglia (metabolism)</term>
<term>Neuroprotective Agents (pharmacology)</term>
<term>Nitric Oxide (metabolism)</term>
<term>Parkinson Disease (therapy)</term>
<term>Rats</term>
<term>Tumor Necrosis Factor-alpha (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Hydrogen Sulfide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Interleukin-6</term>
<term>Levodopa</term>
<term>Nitric Oxide</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Mitochondria</term>
<term>Neuroglia</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Models, Biological</term>
<term>Rats</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>The main lesion in Parkinson disease (PD) is loss of substantia nigra dopaminergic neurons. Levodopa (<sc>l</sc>
-DOPA) is the most widely used therapy, but it does not arrest disease progression. Some possible contributing factors to the continuing neuronal loss are oxidative stress, including oxidation of <sc>l</sc>
-DOPA, and neurotoxins generated by locally activated microglia and astrocytes. A possible method of reducing these factors is to produce <sc>l</sc>
-DOPA hybrid compounds that have antioxidant and antiinflammatory properties. Here we demonstrate the properties of four such <sc>l</sc>
-DOPA hybrids based on coupling <sc>l</sc>
-DOPA to four different hydrogen sulfide-donating compounds. The donors themselves were shown to be capable of conversion by isolated mitochondria to H<sub>2</sub>
S or equivalent SH<sup>−</sup>
 ions. This capability was confirmed by <italic>in vivo</italic>
 results, showing a large increase in intracerebral dopamine and glutathione after iv administration in rats. When human microglia, astrocytes, and SH-SY5Y neuroblastoma cells were treated with these donating agents, they all accumulated H<sub>2</sub>
S intracellularly as did their derivatives coupled to <sc>l</sc>
-DOPA. The donating agents and the <sc>l</sc>
-DOPA hybrids reduced the release of tumor necrosis factor-α, interleukin-6, and nitric oxide from stimulated microglia, astrocytes as well as the THP-1 and U373 cell lines. They also demonstrated a neuroprotective effect by reducing the toxicity of supernatants from these stimulated cells to SH-SY5Y cells. <sc>l</sc>
-DOPA itself was without effect in any of these assays. The H<sub>2</sub>
S-releasing <sc>l</sc>
-DOPA hybrid molecules also inhibited MAO B activity. They may be useful for the treatment of PD because of their significant antiinflammatory, antioxidant, and neuroprotective properties.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><noCountry><name sortKey="Giustarini, Daniela" sort="Giustarini, Daniela" uniqKey="Giustarini D" first="Daniela" last="Giustarini">Daniela Giustarini</name>
<name sortKey="Lee, Moonhee" sort="Lee, Moonhee" uniqKey="Lee M" first="Moonhee" last="Lee">Moonhee Lee</name>
<name sortKey="Mcgeer, Edith" sort="Mcgeer, Edith" uniqKey="Mcgeer E" first="Edith" last="Mcgeer">Edith Mcgeer</name>
<name sortKey="Mcgeer, Patrick L" sort="Mcgeer, Patrick L" uniqKey="Mcgeer P" first="Patrick L." last="Mcgeer">Patrick L. Mcgeer</name>
<name sortKey="Rossi, Ranieri" sort="Rossi, Ranieri" uniqKey="Rossi R" first="Ranieri" last="Rossi">Ranieri Rossi</name>
<name sortKey="Sparatore, Anna" sort="Sparatore, Anna" uniqKey="Sparatore A" first="Anna" last="Sparatore">Anna Sparatore</name>
<name sortKey="Tazzari, Valerio" sort="Tazzari, Valerio" uniqKey="Tazzari V" first="Valerio" last="Tazzari">Valerio Tazzari</name>
</noCountry>
<country name="Italie"><noRegion><name sortKey="Del Soldato, Piero" sort="Del Soldato, Piero" uniqKey="Del Soldato P" first="Piero" last="Del Soldato">Piero Del Soldato</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A53 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A53 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:2878495
   |texte=   Effects of Hydrogen Sulfide-releasing l-DOPA Derivatives on Glial Activation
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:20368333" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Effects of Hydrogen Sulfide-releasing l-DOPA Derivatives on Glial Activation

Effects of Hydrogen Sulfide-releasing l-DOPA Derivatives on Glial Activation

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.